title: Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.
abstract: Particle replication in non-wetting templates (PRINT) is a novel nanoparticle platform that provides compositional flexibility with the ability to specify size and shape in formulating vaccines. The PRINT platform also offers manufacturing and cost advantages over traditional particle technologies. Across multiple antigen and adjuvant formulations, robust antibody and cellular responses have been achieved using PRINT particles in mouse models. Preclinical studies applying PRINT technology in the disease areas of influenza, malaria, and pneumonia are described in this commentary. The proof of principle studies pave the way toward significant cost-effective solutions to global vaccine supply needs.
authors.affiliation: a Liquidia Technologies; Research Triangle Park, NC USA.
authors.forename: Anton
authors.initials: A
authors.lastname: Beletskii
authors.forename: Ashley
authors.initials: A
authors.lastname: Galloway
authors.forename: Shyam
authors.initials: S
authors.lastname: Rele
authors.forename: Michele
authors.initials: M
authors.lastname: Stone
authors.forename: Frank
authors.initials: F
authors.lastname: Malinoski
mesh_terms: D000276:Adjuvants, Immunologic / Q000493:pharmacokinetics*; D000818:Animals; D000941:Antigens / Q000276:immunology*; D004337:Drug Carriers / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007251:Influenza, Human / Q000276:immunology; D008288:Malaria / Q000276:immunology; D053758:Nanoparticles / Q000008:administration & dosage*; D036103:Nanotechnology / Q000379:methods*; D011014:Pneumonia / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D004337:Drug Carriers
keywords: adjuvant; antigen delivery; conjugate vaccine; nanoparticle; nanotechnology; vaccine